Abstract
Ovarian cancer (OC) is one of the leading causes of cancer-related deaths in women both in Asia and worldwide. The NCCN guidelines suggest all newly diagnosed OC patients should take genetic risk evaluation including BRCA1/2 testing. OC patients who have deleterious BRCA1/2 variants are likely to benefit from PARP inhibitors. We aimed to investigate the prevalence and characteristics of BRCA1/2 mutations in Chinese OC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
